US STD Diagnostics Market Insight
US STD Diagnostics market size is growing at a 7.18% CAGR, the current situation has developed because sexually transmitted diseases have increased in prevalence, while people have become more aware of these diseases, screening programs have expanded, and scientists have developed better diagnostic testing methods.
US STD Diagnostics Market Insights Forecasts to 2035
- The US STD Diagnostics Market Size Was Estimated at USD 5265.4 Million in 2025
- The Market Size is Expected to Grow at a CAGR of around 7.18% from 2025 to 2035
- The US STD Diagnostics Market Size is Expected to Reach USD 10534.21 Million by 2035
Notable Insights for US STD Diagnostics Market
- By product type, the molecular diagnostics segment dominated the market, generating approximately USD 2,145.8 million in revenue in 2024.
- By application, the chlamydia testing segment is expected to witness the fastest growth, supported by increasing infection rates and expanding screening initiatives.
- Approximately 65% of diagnostic laboratories have adopted nucleic acid amplification tests (NAATs), while nearly 55% of testing centers are utilizing rapid point-of-care testing solutions, enhancing early detection and treatment outcomes. Additionally, the US holds a significant share of the global STD diagnostics market in 2024, reflecting a strong healthcare infrastructure.
- The US STD Diagnostics Market benefits from government initiatives and public health campaigns which both encourage regular screening and help detect infections at an earlier stage while they reduce the rate at which diseases spread through different groups of people.
Download the eBook (ToC)
Competitive Analysis:
The report offers the appropriate analysis of the key organizations/companies involved within the US STD Diagnostics market, along with a comparative evaluation primarily based on their product of offering, business overviews, geographic presence, enterprise strategies, segment market share, and SWOT analysis. The report also provides an elaborative analysis focusing on the current news and developments of the companies, which includes product development, innovations, joint ventures, partnerships, mergers & acquisitions, strategic alliances, and others. This allows for the evaluation of the overall competition within the market.
Top Companies in US STD Diagnostics Market
- Abbott Laboratories
- F. Hoffmann-La Roche Ltd
- Danaher Corporation
- Becton, Dickinson and Company
- Hologic Inc.
- Siemens Healthineers
- bioMerieux
- Others
Recent Developments:
- In March 2026, Abbott Laboratories introduced new advanced molecular diagnostic tests which detect sexually transmitted infections and provide better accuracy and quicker testing results and superior detection capabilities for various pathogens.
- In October 2024, Hologic Inc. expanded its molecular diagnostics portfolio with new high-throughput systems designed for STD testing, which enhanced laboratory operations and enabled organizations to conduct extensive testing programs.
Market Segmentation:
US STD Diagnostics Market, By Product Type
- Molecular Diagnostics
- Immunoassays
- Rapid Tests
- Others
US STD Diagnostics Market, By Application
- Chlamydia Testing
- Gonorrhea Testing
- Syphilis Testing
- HIV Testing
- Others
US STD Diagnostics Market, By End User
- Hospitals
- Diagnostic Laboratories
- Homecare Settings
- Others
Expert Views:
The US STD Diagnostics Market will experience steady growth because increasing disease rates and the introduction of new diagnostic technologies will drive market expansion. Experts highlight that rapid testing and molecular diagnostics together with expanding screening programs will create essential elements which will enhance early detection capabilities while driving overall market development.